Accelerating vaccine research for COVID-19 with high-performance computing and artificial intelligence
on the May 14, 2020
- HPE is powering research to accelerate discovery of antibodies, antiviral agents and drug candidates to be tested for vaccine development.
- U.S. DOE's Argonne National Laboratory, Lawrence Livermore National Laboratory and GENCI dedicate HPC and AI technologies to improve speed and accuracy of molecular dynamics simulations.
(More information)
Published on July 8, 2020
